Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WBRT versus WBRT plus Endostar for multiple brain metastases from small-cell lung cancer
ChiCTR1900020685Phase 2Not yet recruiting
- Sponsor
- Department of Oncology, Sanming First Hospital of Fujian Medical University
- Start
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of endostar in small cell lung cancer (SCLC) and brain metastases (2 arms), sponsored by Department of Oncology, Sanming First Hospital of Fujian Medical University. Primary endpoint: intracranial progression-free survival. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
endostar
03
Conditions
small cell lung cancer (SCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR1900020685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020685.